The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Fixed-duration glofitamab monotherapy in R/R MCL: 3.5-year follow-up data
Joshua Brody, MD, The Tisch Cancer Institute at Mount Sinai, New York City, NY, shares updated results from the 3.5-year follow-up of a study (NCT03075696) evaluating fixed-duration glofitamab monotherapy, given with step-up dosing after obinutuzumab pretreatment, for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) with or without prior BTK inhibitor exposure. Dr Brody reports high efficacy rates and manageable toxicities. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
